In 2016, TB sickened 10.4 million people globally, resulting in 1.7 million deaths, according to data from the World Health Organization. 2016 also marked an increase in cases where TB gained resistance to current therapies.
For the study, researchers used X-ray to examine the Mycobacterium tuberculosis bacteria and discovered a specific type of enzyme that, when attacked, creates a pathway to kill the TB cell.
“Tuberculosis is a major global health problem and the current drugs that we use today are over 40 years old. It is therefore vital that we discover new therapeutic agents to combat TB,”says Elizabeth Fullam, PhD, a fellow at the University of Warwick’s School of Life Sciences in England, told Futurity.
This new knowledge of the enzyme’s function will help , scientist, researchers and drugmakers alike develop new drugs for TB.
More articles on clinical leadership and infection control:
Many Ebola survivors grapple with debilitating neurological issues, study finds
Medical schools use innovative holograms to train nurses
7 insights into the NYC organ transplant crisis
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
